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Purpose: There are few studies that have focused on the predictors of recurrence after gastrectomy for gastric carcinoma. This study 
analyzed the patients who died of recurrent gastric carcinoma and we attempted to clarify the clinicopathologic factors that are associ-
ated with the timing of recurrence. 
Materials and Methods: From June 1992 to March 2009, 1,795 patients underwent curative gastric resection at the Department of 
Surgery, Hanyang University College of Medicine. Among them, 428 patients died and 311 of these patients who died of recurrent gas-
tric carcinoma were enrolled in this study. The clinicopathologic findings were compared between the 72 patients who died within one 
year after curative gastrectomy (the early recurrence group) and the 92 patients who died 3 years after curative gastrectomy (the late 
recurrence group).
Results: Compared with the late recurrence group, the early recurrence group showed an older age, a more advanced stage, a poorly differ-
entiated type of cancer and a significantly higher tendency to have lymphatic invasion, vascular invasion and perineural invasion.Especially 
in the gastric cancer patients with a more advanced stage (stage III and IV), the early recurrence group was characterized by a significantly 
higher preoperative serum carcino embryonic antigen level, perineural invasion and a relatively small number of dissected lymph nodes. 
Conclusions: The clinicopathologic characteristics of recurrent gastric cancer are significantly different according to the stage of disease, 
and even in the same stage. For the early detection of recurrence after curative surgery, it is important to recognize the clinicopathologi-
cal factors that foretell a high risk of recurrence. It is mandatory to make an individualized surveillance schedule according to the clinico-
pathologic factors.
Key Words: Stomach neoplasms, Gastrectomy, Recurrence
Original Article J Gastric Cancer 2011;11(1):46-54 y DOI:10.5230/jgc.2011.11.1.46
Correspondence to: Sung Joon Kwon
Department of Surgery, Hanyang University College of Medicine, 17, 
Haengdang-dong, Seongdong-gu, Seoul 133-792, Korea
Tel: +82-2-2290-8453, Fax: +82-2-2281-0224 
E-mail: sjkwon@hanyang.ac.kr
Received September 24, 2010
Accepted November 25, 2010
Introduction
The incidence of gastric cancer has recently been gradually 
decreasing, and particularly the proportion of cases of early 
gastric cancer among all the cases of gastric cancer is rapidly on 
the rise. Yet the mortality rate due to gastric cancer is still high.
(1,2) Surgical resection is currently the only radical treatment for 
gastric cancer, and the 5-year survival rate is continuously on 
the increase because of performing radical resection, extended 
lymphadenectomy, postsurgical chemotherapy and adjuvant 
immunotherapy. Nevertheless, death is due to recurrence in 
60~70% of the cases of gastric cancer.(3) In some cases, it can 
be resected again, which allows long term survival. Yet gastric 
cancer recurs as diverse patterns in several organs, and it is difficult 
to distinguish the recurrence patterns. Hence, this is treated by 
conservative treatments, and prognosis is poor.(4-6) The level 
of tumor infiltration and the presence or absence of lymph node 
metastasis are currently the important prognostic factors, but there 
are insufficient studies on the risk factors pertinent to the time of 
recurrence or the recurrence patterns. To understand the factors 
associated with recurrence and to help appropriately treat the 
at-risk group after surgery, we analyzed the clinicopathological 
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characteristics of patients with the same disease stages according to 
the time of recurrence. 
Materials and Methods
From June 1992 to March 2009, in the Department of Surgery 
at Hanyang University, 1,795 patients were diagnosed with gastric 
cancer and 428 of them died. Among them, we excluded the 
patients that the cause of death was not known (n=50), the patients 
who died due to accidents (n=11), the patients who died due to 
cancer in other organs (n=17) and the patients who died of other 
benign diseases (n=39). Finally, this study was conducted on 311 
patients who died due to recurrent gastric cancer (Table 1). A 
radical resection was done for the patients without distant metastasis 
and without infiltration to the adjacent organs, the patients with 
infiltration and without macroscopic residual cancer and the 
patients who underwent lymphadenectomy higher than D2.
These 311 patients were divided to 1) 72 patients (23.2%) (the 
early recurrence group) whose recurrence time was within 1 year 
after surgery, 2) 92 patients (29.6%) (the late recurrence group) 
whose recurrence occurred 3 years after surgery and 3) 147 
patients (47.2%) (the mid recurrence group) who had recurrent 
disease between 1 year to 3 years after surgery (Fig. 1), and the 
clinicopathological characteristics of the early recurrence group and 
the late recurrence group were compared and analyzed.
History taking, physical examination, general blood tests, 
biochemistry tests, tumor marker tests, chest X-rays, gastroscopic 
examination, abdominal ultrasonography, abdominal computed 
tomography and PET-CT were regularly performed at the 
postsurgical ambulatory follow-up. 
The recurrence patterns were classified as local recurrence, 
peritoneal recurrence and hematogenous recurrence. The local 
recurrence group was defined as cases that according to the clinical 
findings or various test findings, the gastric cancer recurred in the 
remaining stomach, the anastomosis areas and the adjacent organs 
and lymph nodes. According to physical examination, abdominal 
plain radiography and abdominal computed tomography, peritoneal 
Table 1. Patterns of recurrence after curative surgery in gastric 
cancer
Cause of death No. of patients
Peritoneal seeding 170
Hematogenous recurrence 57
Liver 29
Lung 11
Bone 8
Brain 7
Abdominal wall 2
Locoregional recurrence 29
Remnant stomach 6
Gastric bed 6
Lymph node 17
Not defi  ned recurrence site 55
Benign disease 39
Pneumonia 8
Myocardial infarcion 7
Hepatic failure 7
Pulmonary embolism 4
Renal failure 3
Others 10
Other organ cancer 17
Cholangiocellcarcinoma 5
Lung cancer 3
Colorectal cancer 3
Leukemia 2
Hepatocellularcarcinoma 1
Pancreatic cancer 1
Esophageal cancer 1
Multiple myeloma 1
Accident 11
Unknown origin 50
Total death  428
Stomach cancer 311
Others 67
Unknown 50 Fig. 1. Frequency of recurrence aft  er curative operation.Choi JY, et al.
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recurrence was defined as the cases with tumors within the 
abdominal cavity, the cases with cancers detected by an ascites 
test, the cases in which diffuse metastasis was detected within 
the abdominal cavity during resurgery and the cases with tumor 
palpated on the rectal shelf by physical examination. Hematogenous 
recurrence was defined as the cases with hematogenous metastasis 
to distant organs such as the liver, bone, brain, abdominal wall etc., 
and this was detected by chest X-ray, abdominal sonography, a 
total bone scan, other radiologic tests and biopsy.
SPSS 13.0 was used for all the statistical analyses. Student’s 
t-test was applied for comparing the various clinicopathological 
characteristics associated with recurrence. Logistic regression tests 
were applied for the multivariate analysis. P-values ＜0.05 were 
considered to be statistically significant.
Results
1. The interval from surgery to recurrence
The interval of the 311 patients who died of recurred gastric 
cancer after radical treatment was from a minimum of 2 months 
to a maximum of 147 months, the average follow-up period was 
30 months and the mean age was 56.2 years. Among them, the 
number of patients who recurred within 1 year was 72 patients, 
which was 23.2% of all the patients. The number of patients who 
recurred after 3 years was 92 patients, and they accounted for 
29.6% of all the patients (Fig. 1). The cumulative recurrence rate up 
to 2 years after surgery was 39.2%, and the recurrence rate at the 
third year was 79.4% (Fig. 2).
2. The recurrence pattern 
In regard to the recurrence pattern of all 311 patients, there 
were 170 patients with peritoneal recurrence, which was the most 
prevalent, 57 patients with hematogenous recurrence and 29 patients 
with local recurrence. There were 55 patients whose recurrence area 
Fig. 2. Cummulativee rate of recurrence aft  er curative resection.
Table 2. Clinicopathological findings according to the timing of 
recurrence aft  er curative surgery in gastric cancer
Factors
Early recurrence
(≤1 year)
Late recurrence
(>3 years) P-value
n=72 % n=92 %
Sex
Male 46 63.89 57 61.96 NS
Female 26 36.11 35 38.04
Age (yr)
<59 32 44.44 57 61.96 0.025
≥59 40 55.56 35 38.04
Operation
Subtotal gastrectomy 38 52.78 58 63.04 NS
Total gastrectomy 34 47.22 34 36.96
TNM stage (6th AJCC)
I  1  1.39 12 13.03 <0.0001
II  3  4.17 17 18.48
III 26 36.11 40 43.48
IV 42 58.33 23 25.01
Chemotherapy
None  5  6.94  9  9.78 NS
Oral 10 13.89 20 21.74
Systemic 57 79.17 63 68.48
Lymph node dissection
D2 48 66.67 61 66.31 NS
>D2 24 33.33 31 33.69
Dissected lymph node (No)
<45 45 62.50 48 52.17 NS
≥45 27 37.50 44 47.83
Lymphatic invasion
Positive 66 91.67 73 79.35 0.029
Negative  6  8.33 19 20.65
Blood vessel invasion
Positive 25 34.72 19 20.65 0.044
Negative 47 65.28 73 79.35
Perineural invasion
Positive 23 31.94 10 10.87 0.001
Negative 49 68.06 82 89.13
Preoperative CEA (ng/ml)
<5 52 73.61 73 79.35 NS
≥5 16 22.22 12 13.04
Unknown  3  4.17  7  7.61Recurrence Timing after Curative Gastrectomy
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was not clear, but they were confirmed to have recurrent gastric 
cancer (data from the Bureau of Statistics) (Table 1). 
3. Clinicopathological characteristics according to 
the recurrence time
The clinicocharacteristics of the early recurrence group and 
the late recurrence group were compared. Regarding the age 
distribution, the age of the early recurrence group was higher 
(P=0.025). Regarding the distribution according to the 6th AJCC 
staging system an advanced disease stage was more prevalent in the 
early recurrence group than in the late recurrence group (P＜0.001). 
In addition, the cases with lymph node infiltration, vascular 
infiltration or perineural infiltration were significantly more 
prevalent in the early recurrence group than in the late recurrence 
group (P=0.029, P=0.044, P=0.001). Concerning the grade of 
histological differentiation, the cases with poorly differentiated 
histological types were significantly more abundant in the early 
recurrence group than in the late recurrence group (P=0.019) (Table 
2).
Other than that, age, the surgical methods, additional adjuvant 
therapy, the range of lymphadenectomy, the number of resected 
lymph nodes and the presurgical serum CEA and CA19-9 values 
of the two groups were not significantly different.
 Multivariate analysis was performed using logistic regression on 
age, the 6th AJCC staging system lymph node infiltration, vascular 
infiltration and perineural infiltration, which were all significant on 
the univariate analysis. It was observed that for the early recurrence 
cases, the stastically significant factors were an advanced stage (stage 
III), perineural infiltration and age (Table 3).
4. Clinicopathological characteristics of the stage III and 
IV patients according to the recurrence time
Among the patients, for the stage III and stage IV patients 
whose incidence of recurrence was particularly high, we compared 
the clinicopathological characteristic according to the recurrence 
time for the patients with the same disease stage. In regard to the 
Table 3. Multivariate analysis* (logistic regression test) of clinicopathologic factors according to early and late recurrence group
P-value Odds ratio 95% confi  dence interval
Age (≥58 years) 0.045 0.467 0.222~0.985
Perineural invasion 0.023 0.329 0.127~0.856
TNM stage
Stage II 0.564 0.475 0.038~5.952
Stage III 0.066 0.120 0.013~1.147
Stage IV 0.042 0.004~0.433
 TNM = tumor node metastasis. *Binary logistic regression with “enter” method.
Table 2. Continued
Factors
Early recurrence
(≤1 year)
Late recurrence
(>3 years) P-value
n=72 % n=92 %
Preoperative CA19-9 (U/ml)
<39 68 94.44 89 96.74 NS
≥39  3  4.17  3  3.26
Unknown  1  1.39  0 0
Site
Lower third 38 52.78 41 44.57 NS
Middle third 20 27.78 38 41.3
Upper third 10 13.89 10 10.86
Entire  stomach  4  5.55  3  3.27
Tumor size(cm)
<8 39 54.17 56 60.87 NS
≥8 33 45.83 36 39.13
Histology
Well diff   erentiated  0 0  3  3.26 0.019
Moderate diff  erentiated 16 22.22 27 29.35
Poorly diff  erentiated 36 50 27 29.35
Signet ring cell 20 27.78 30 32.61
Mucinous  0 0  5  5.43
Type of recurrence
Peritoneal seeding 37 51.39 42 45.65 NS
Hematogenous 18 25.00 13 14.13
Locoregional 15 20.83 25 27.17
Unknown  origin  2  2.78 12 13.05
NS = not signifi  cant; TNM = tumor node metastasis; CEA = carcino 
embryonic antigen.Choi JY, et al.
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number of resected lymph nodes (median value: 47), there were 
significantly fewer cases with more than 47 lymph nodes in the 
early recurrence group than in the late recurrence group (P=0.020), 
and perineural infiltration was significantly more abundant in the 
early recurrence group (P=0.001) (Table 4).
Multivariate analysis was performed by applying Logistic 
regression on the number of resected lymph nodes as well as 
perineural infiltration, which were significant on univariate analysis. 
It was observed that only perinerual infiltration was significantly 
more prevalent in the early recurrence group (P=0.006) (Table 5).
Discussion
The incidence and mortality rate of gastric cancer are on the 
decrease, and due to the development of diagnostic methods, 
the rate of discovering early gastric cancer as well as the 5-year 
Table 4. Clinicopathological findings according to the timing of   
recurrence in stage III and stage IV gastric cancer
Factor
Early recurrence
(≤1 year)
Late recurrence
(>3 years) P-value
n=68 % n=63 %
Sex
Male 42 61.76 37 58.73 NS
Female 26 38.24 26 41.27
Age (yr)
<57 30 44.12 36 57.14 NS
≥57 38 55.88 27 42.86
Operation
Subtotal gastectomy 34 50 35 55.56 NS
Total gastrectomy 34 50 28 44.44
Chemotherapy
None  3  4.41  3  4.76 NS
Oral 10 14.7 11 17.46
Systemic 55 80.89 49 77.78
Dissected lymph node (No)
<47 48 70.59 32 50.79 0.020
≥47 20 29.41 31 49.21
Lymphatic invasion
Positive 64 94.11 57 90.48 NS
Negative  4  5.89  6  9.52
Blood vessel invasion
Positive 23 33.82 14 22.22 NS
Negative 45 66.18 49 77.78
Perineural invasion
Positive 22 32.35  6  9.52 0.001
Negative 46 67.65 57 90.48
Size (cm)
<7 36 52.94 35 55.56 NS
≥7 32 47.06 28 44.44 NS
Factor
Early recurrence
(≤1 year)
Late recurrence
(>3 years) P-value
n=68 % n=63 %
Site
Lower third 36 52.94 27 42.86 NS
Middle third 18 26.47 23 36.51
Upper third 10 14.7 10 15.87
Entire  stomach   4 5.89  3  4.76
Histology
Diff  erentiated 15 22.06 16 25.4 NS
Undiff  erentiated 53 77.94 47 74.6  
Preoperative CEA (ng/ml)
<5 49 72.06 51 80.95 NS
≥5 16 23.53  6  9.52
Unknown  3  4.41  6  9.52
Preoperative CA19-9 (U/ml)
<39 65 95.59 60 95.24 NS
≥39  3  4.41  3  4.76
Type of recurrence
Peritoneal seeding 38 55.88 32 50.79 NS
Hematogenous 17 25  6  9.52
Locoregional  6  8.82  5  7.94
Unknown origin   7 10.3 20 31.75
NS = not signifi  cant; CEA = carcino embryonic antigen.
Table 4. Continued
Table 5. Multivariate analysis* (logistic regression test) of clinicopathologic factors according to early and late recurrence group in stage III and 
stage IV gastric cancer
P-value Odds ratio 95% confi  dence interval
Perineural invasion 0.006 0.250 0.092~0.678
*Binary logistic regression with “enter” method.Recurrence Timing after Curative Gastrectomy
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survival rate are gradually increasing.(1,2) Numerous studies on the 
clinicopathological characteristics that exert effects on the prognosis 
of gastric cancer have been conducted, and prognosis can be 
predicted by the level of the infiltration of tumors to the stomach 
wall and the presence of lymph node metastasis and distant 
metastasis, which are the basis of the classification of the disease 
stage of gastric cancer.(7) Nevertheless, despite the improved 
diagnostic methods and extended therapeutic resection, the percent 
of cases that recur within 2 years after surgery has been reported 
to be 60~70%(3-6) In such a manner, most cases of mortality are 
associated with recurrence. Studies on the factors associated with 
the recurrence of gastric cancer are ongoing, but the information on 
this is still not sufficient. 
Generally, recurrence refers to the growth of cancer lesions 
pertinent to the primary caner after radical resection is performed 
according to the objective decision of surgeons.(8) The aim of 
radical resection of gastric cancer is first to completely remove the 
primary lesions with appropriate margins and second to prevent 
metastasis of cancer by the complete resection of the lymph nodes 
in the vicinity of the stomach.(9) In regard to distant metastasis 
that develops after such radical resection, the possibility is high 
that cancer has already formed beyond the range of surgery and at 
the time of surgery. Regarding local metastasis, the possibility of 
the presence of microscopical residual cancer cells is high. When 
reviewing the characteristics of recurrence according to the advanced 
level of cancer, in patients with progressive stomach cancer, the 
progression routes are diverse such as lymphoid, hematogenous and 
direct infiltration, peritoneal dissemination, etc. In most cases, the 
cancer progresses by several routes and not by a single route. On 
the other hand, in patients with early gastric cancer, progression is 
caused by overlooking multiple lesions, incomplete resection without 
securing sufficient margins after radical resection and insufficient 
lymphadenectomy in most cases.(9,10)
In most studies, recurrence has been classified as the early 
recurrence group and the late recurrence group based on 2 years 
and 3 years, respectively, and the risk factors associated with 
recurrence or the survival period after recurrence were analyzed.
(6,11-16) This is based on the observation that for approximately 
70% of recurred patients, the cancer recurs within 2 years after 
surgery, and cases that recur after 5 years are rare.(15)
Shiraishi et al.(11) classified 138 patients who died of recurrence 
after radical stomach resection as 104 cases (75.36%) of the early 
recurrence group (recurred within 2 years after surgery) and 34 
cases (24.64%) of the late recurrence group (recurred after 2 years), 
and they compared the clinicopathological characteristics. It was 
observed that in the early recurrence group, the average size of 
tumors was significantly larger (P＜0.01) and the cases with lymph 
node metastasis (P=0.01), lymph duct infiltration (P＜0.01) and 
advanced disease stages (P=0.01) were significantly more abundant.
In addition, Yokota et al.(14) classified 251 patients who died 
of recurrence after radical stomach resection as the group that 
recurred within 2 years and the group that recurred after 2 years. 
In regard to the incidence of recurrence and the timing, there 
were 195 patients (77.69%) and 56 patients (22.31%) in each group, 
respectively, and the early recurrence group was larger. In the early 
recurrence group, the size of tumor was significantly larger (P=0.029). 
In addition, serous infiltration (P=0.038), lymph node metastasis 
(P=0.001), and the incidence of vascular infiltration (P＜0.001) were 
significantly higher in the early recurrence group. 
Efforts have recently been made to apply immunohistochemical 
staining to find predictive factors for recurrence after radical 
resection of gastric cancer, in addition to the previously determined 
clinicopathological factors. Kim et al.(17) compared the expressions 
of c-erbB2, EGFR, MLH1, MSH2 and aquaporins of the recurred 
group with early gastric cancer after therapeutic radical resection 
with those of the non-recurrence group with early gastric cancer. 
They reported that the expression of c-erb B2 was significantly 
higher in the recurrence group (P=0.024).
In this current study, based on 72 patients (23.2%) whose 
recurrence time was within 1 year and 92 patients (29.6%) whose 
recurrence time was longer than 3 years, the patients who died 
of recurred gastric cancer after radical resection were divided to 
the early recurrence group, the mid recurrence group and the late 
recurrence group. Different from most studies(6,9,11-13) that 
classified patients based on 2 years after surgery.
In this study we defined the early recurrence group based on the 
approximately early 25% cases of all recurrence cases and the late 
recurrence group based on the approximately late 25% cases of all 
recurrence cases.
Thus, if recurrence could be detected early based on our study’
s data, this could be an important for more aggressive therapies for 
recurrent lesions rather than just performing radical resection. In 
the early recurrence group, as compared with the late recurrence 
group, an advanced disease stage was more prevalent, the mean 
age was higher, the incidence of vascular, lymph duct and 
perineural infiltration was higher and the histological types with 
poor differentiation were more abundant. Particularly, for the 
patients with a highly advanced gastric cancer (stage III, stage IV), Choi JY, et al.
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perineural infiltration was abundant in the early recurrence group, 
and there were significantly more cases with a relatively small 
number of dissected lymph nodes. In such a manner, although 
the recurrence time was different according to the disease stages, 
within a same disease stage, some clinicopathological factors 
showed significant differences according to the recurrence time.
Lymph node metastasis is a well known prognostic factor 
that exerts effects on the recurrence rate as well as the overall 
survival rate. Tumor cells released from primary lesions penetrate 
the basement membrane, they transverse the interstitial tissues 
and penetrate the vascular basement membrane, they enter the 
circulation system and then they form tumor cell embolism. They, 
in turn, are released again through the basement membrane and 
form distant metastatic lesions. In addition, it has been reported 
that perineural infiltration, which has already been recognized 
as a major factor that mediates effects on tumor recurrence after 
surgery in patients with pancreas, biliary tract, esophagus and 
coloreactal cancer, is associated with the recurrence of gastric 
cancer.(18-20) Bilici et al.(18) analyzed the perineural infiltration 
of 238 patients who underwent radial gastrectomy, and it was 
observed that 180 patients (75.6%) showed perineural infiltration. 
When their clinicopathological characteristics were analyzed and 
compared with those of the group without perineural infiltration, 
the average size of tumor was significantly larger (P＜0.001), the 
differentiation grade was worse (P=0.009) and an advanced disease 
stage (P＜0.001), lymph node metastasis (P＜0.001) and vascular 
infiltration (P＜0.001) were significantly more abundant. In 
addition, the average survival period of the group with perineural 
infiltration was 28.1 months, and it was significantly shorter than 
64.9 months of the group without perineural infiltration (P=0.001). 
Perineural infiltration is a process of tumor infiltration due to the 
neurotropic properties of tumor cells and it refers to the process of 
the denaturation of nerve fibers due to tumor cells infiltrating nerve 
bundles or nerve sheaths in the vicinity of tumors. Examined under 
an electronic microscope, nerve sheaths, lymph ducts and blood 
vessels are connected to each other anatomically, and through 
this, tumor cells infiltrate to adjacent tissues through the nerve 
sheaths and then they disseminated into the lymphoid system and 
toward the peritoneal membrane. Therefore, for cases with lymph 
node metastasis or perineural infiltration, even if radical resection 
is performed, the possibility of recurrence is high. It has been 
suggested that the follow-ups should be regularly performed and 
this may be of help to detect recurrence early. 
For making the diagnosis of recurrence, not only imaging 
tests, but also tumor markers, hepatic function tests, general blood 
tests and other hematological tests are applied. Currently at our 
hospital, after radical gastrectomy and depending on the disease 
stage, different categories of tests and test intervals are applied. In 
Table 6. Post-operative surveillance schedule according to stage
3M 6M 9M 12M 15M 18M 21M 24M 27M 30M 33M 36M 42M 48M 54M 60M
Stage I/II
CBC/LFT O O O O O O OOOOO
CXR O O O O O
CT/US O O O O O O O
PET-CT O O O O
EGD O O O O O
T M O O O O O OOOOO
Stage III/IV
CBC/LFT O O O O O O O OOOOOOOOO
C X R O O O O O OOOOO
CT/US O O O O O O O O
PET-CT O O O O O
EGD O O O O O
T M O O O OOOOOOOOOOOOO
CBC = complete blood count; LFT = liver function test; CXR = chest X-ray; CT = abdomen couputed tomography; US = abdomen 
ultrasonography; EGD = esophagogastroduodenoscopy; TM = tumor marker.Recurrence Timing after Curative Gastrectomy
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other words, for stage I and stage II patients, general blood tests, 
hepatic function tests and tumor marker tests are performed at 6 
month intervals. Abdominal computed tomography is performed at 
6 month intervals up to 18 months after surgery, and at 12 month 
intervals after 18 months. In addition, gastroscopy is performed 
for the first time 6 months after surgery and at 12 month intervals 
afterward. PET-CT is performed 24 months after surgery for 
the first time. For the highly advanced cancer stage III and stage 
IV patients, since the risk of recurrence is high, general blood 
tests, liver function tests and tumor marker tests are performed 
at 3 month intervals, and abdominal computed tomography is 
performed 3 months after surgery for the first time and then at 
6 month intervals afterward. PET-CT as well as gastroscopy are 
performed 6 months after surgery for the first time, and at 12 
month intervals afterward (Table 6). In such a manner, the follow-
up observation is performed differently according to the disease 
stage in order to detect recurrence after surgery early and to 
facilitate establishing treatment plans accordingly.
It is clear that an early diagnosis and radical resection during 
the initial surgery are the most important factors to increase the 
survival rate and to lower the recurrence rate. It is also true that 
with the development of chemotherapy, immunotherapy and 
other diverse therapies, the survival rate and treatment outcomes 
are improving.(21-23) Nonetheless, gastric cancer recurs after 
surgery in many patients, and once cancer recurs, the prognosis is 
very poor because definite treatments have not been established.
(24-26) Gastric cancer is different from other cancers, it recurs as 
asynchronous multicentric cancer rather than locally, and so radical 
resection is difficult in many cases, and the cancer’s responsiveness 
to systemic treatments such as chemotherapy is poor(25-27) 
Gastric cancer shows complex patterns of recurring at diverse times 
and the studies on factors that can predict the recurrence time are 
not still sufficient. 
However, it has been reported that after radical resection, the 
survival rate can be increased through efforts to detect recurrence 
early by regular examination as well as by determining the 
appropriate range of surgery and performing radical treatments 
after the definite diagnosis.(28-30) From July 1988 to December 
1995, Kim et al.(28) examined the clinicopathological characteristic 
of patients who developed local metastasis in the remaining 
stomach after radical gastrectomy, and the gastric cancer was 
primarily diagnosed by gastroscopy and an upper gastrointestinal 
series. The CEA level was elevated in 4 cases, and N2 and N3 
group lymph node infiltration was abundant. It has been reported 
that in such local recurrence cases caused by residual cancer, at the 
time of detection, the progression level of the lesion was severe 
and so the prognosis was poor. Nonetheless, in regard to clinically 
significant factors, it is thought that more comprehensive follow-up 
observation should be performed if the above findings are detected 
by presurgical tests as well as postsurgical tests. Moreover, it has 
been suggested that studies on methods that could be of help to 
improve the survival rate after recurrence are required.
Therefore, not only improving the quality of life according to 
radical treatments, but also the prevention of recurrence as well as 
the early detection of recurrence are important as study subjects. 
It has been shown that the clinicopathological characteristics of 
primary cancer are associated with the recurrence patterns and 
the recurrence time, and so if appropriate follow-up observation 
is performed on the factors that were significant in this study, 
recurrence could be detected early and then properly treated, and 
the mortality rate of gastric cancer itself could be decreased. For 
this, among various clinicopathological factors, efforts should be 
made to find new predictive factors that are clearly correlated with 
the recurrence of gastric cancer. In addition, studies on surgery, 
chemotherapy and other optimal treatment methods according to 
such correlation are also required.
In gastric cancer patients who recurred after radical resection, 
according to the disease stages and even in the same disease stage, 
the characteristics and time of recurrence vary according to diverse 
clinicopathological factors. Therefore, by considering this, if the 
interval of postsurgical follow-up observation and the types of tests 
are individualized, this would be useful to detect recurrence early 
and it would be of great help to improve the prognosis through 
appropriate treatments at early times.
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